These combined findings indicate that PIK3C2A and TXNIP may play inflammatory roles in the development of CAD and suggest that PIK3C2A may be a novel therapeutic focus in CAD, which requires further studies with the follow-up of involved participants. Here, PIK3C2A is linked to coronary artery disorder.